AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
191.76
-1.04 (-0.54%)
At close: 4:00PM EDT

191.55 -0.21 (-0.11%)
After hours: 7:28PM EDT

Stock chart is not supported by your current browser
Previous Close192.80
Open191.86
Bid191.52 x 900
Ask191.77 x 800
Day's Range190.29 - 192.77
52 Week Range163.31 - 201.23
Volume2,089,747
Avg. Volume3,043,219
Market Cap126.889B
Beta1.73
PE Ratio (TTM)62.83
EPS (TTM)3.05
Earnings DateJul 26, 2018
Forward Dividend & Yield5.28 (2.72%)
Ex-Dividend Date2018-05-16
1y Target Est196.10
Trade prices are not sourced from all markets
  • Bullish options traders target Amgen, this energy ETF
    CNBC Videos10 days ago

    Bullish options traders target Amgen, this energy ETF

    "Halftime Report" trader Pete Najarian and Mad Money's Jim Cramer discuss unusual options activity in Amgen and the XOP energy ETF.

  • PR Newswire8 hours ago

    Amgen And Cedars-Sinai Partner For Improved Healthcare Quality

    THOUSAND OAKS, Calif. and LOS ANGELES, July 19, 2018 /PRNewswire/ -- Amgen (AMGN) and Cedars-Sinai Medical Center today announced a partnership to help support the improvement of healthcare quality in the treatment of multiple therapeutic areas that could include oncology, cardiovascular disease, osteoporosis and migraine. The organizations intend to jointly undertake research projects in one or more of these therapeutic areas. Proposed initial projects under the three-year agreement focus on cancer therapies, in line with Cedars-Sinai's ranking as Southern California's largest provider of oncology services and Amgen's leadership in the field.

  • AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.
    Zacks2 days ago

    AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.

    AbbVie (ABBV) strikes a deal with Mylan to launch its biosimilar Humira in the United States on Jul 31, 2023.

  • PR Newswire2 days ago

    Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma

    THOUSAND OAKS, Calif., July 18, 2018 /PRNewswire/ -- Amgen (AMGN) today announced the launch of Myeloma MVPTM, a national campaign to help those affected by multiple myeloma create their Most Valuable Plan, an individualized approach for managing their disease. Multiple myeloma is an incurable blood cancer for which there are a variety of treatment options, requiring patients to work closely with their doctors to determine the right plan to meet their needs.

  • Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates
    Zacks2 days ago

    Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates

    It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.

  • Pacira Focused on Exparel Development Amid Competition
    Zacks3 days ago

    Pacira Focused on Exparel Development Amid Competition

    Pacira (PCRX) focuses on the label expansion of its flagship product, Exparel.

  • Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population
    Zacks4 days ago

    Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population

    FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.

  • Better Buy: Biogen Inc. vs. Amgen
    Motley Fool5 days ago

    Better Buy: Biogen Inc. vs. Amgen

    Biogen and Amgen have been two of the best performing biotechs for a decade. But one stock clearly has an easier path toward value creation.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Over the last one-month, outflows of investor capital in ETFs holding AMGN totaled $140 million.

  • Better Buy: Amgen Inc. vs. Johnson & Johnson
    Motley Fool7 days ago

    Better Buy: Amgen Inc. vs. Johnson & Johnson

    Which stock wins in a head-to-head match-up between these huge drugmakers?

  • Is the Options Market Predicting a Spike in Amgen (AMGN) Stock?
    Zacks7 days ago

    Is the Options Market Predicting a Spike in Amgen (AMGN) Stock?

    Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately.

  • Benzinga7 days ago

    Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 12) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Arbutus Biopharma ...

  • 2 Overlooked Biotech Stocks to Buy Now
    Motley Fool7 days ago

    2 Overlooked Biotech Stocks to Buy Now

    The industry's biggest players just aren't getting the attention their cash flows deserve.

  • PR Newswire7 days ago

    Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA

    THOUSAND OAKS, Calif. and BRUSSELS, July 12, 2018 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY™* (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY increases bone formation and reduces bone resorption simultaneously to increase bone mineral density (BMD) and reduce the risk of fracture. "A fracture due to osteoporosis can be a life-altering event, and EVENITY has the potential to reduce fracture risk in patients at high risk due to a prior fracture," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

  • Investopedia7 days ago

    7 High-Margin Stocks Poised to Beat the Market

    As the economy reaches the later stages of its cycle and profit growth slows, investors should take a look at Goldman Sachs’ basket of more than 30 Russell 1000 stocks with high gross profit margins that have proven stable over time. Seven of those stocks, which have been recent outperformers, include Verisign Inc. ( VRSN), Amgen Inc. ( AMGN), Cadence Design Systems Inc. ( CDNS), Adobe Systems Inc. ( ADBE), IDEXX Laboratories Inc. ( IDXX), Liberty Media Corp. ( LSXMA) and O’Reilly Automotive Inc. ( ORLY).

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGN

  • Your first trade for Wednesday, July 11
    CNBC9 days ago

    Your first trade for Wednesday, July 11

    The "Fast Money" traders share their first moves for the market open.

  • 3 Huge Biotech Winners in 2018 (So Far)
    Motley Fool9 days ago

    3 Huge Biotech Winners in 2018 (So Far)

    Why these stocks are the best biotech performers so far this year.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Over the last one-month, outflows of investor capital in ETFs holding AMGN totaled $820 million.

  • Moving Average Crossover Alert: Amgen (AMGN)
    Zacks10 days ago

    Moving Average Crossover Alert: Amgen (AMGN)

    Amgen Inc. (AMGN) is looking like an interesting pick from a technical perspective

  • Incyte’s Valuations on July 6
    Market Realist10 days ago

    Incyte’s Valuations on July 6

    According to Incyte Corporation (INCY), the firm is a “Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.”

  • ACCESSWIRE11 days ago

    Today's Research Reports on Stocks to Watch: Biogen and Amgen

    Shares of Amgen also moved north as Wall Street's celebration of Biogen's news pushed many biotech stocks higher. Biogen Inc. shares were jumping on Friday, closing the day up almost 20% on high volume compared to usual. The company along with Eisai Co. Ltd. of Japan had announced positive results from an Alzheimer's study.

  • Why Biotech Stocks Rallied on Biogen's Alzheimer's Test
    Zacks13 days ago

    Why Biotech Stocks Rallied on Biogen's Alzheimer's Test

    Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.

  • TheStreet.com13 days ago

    Biotech Stocks Rally on Biogen's Landmark Test

    The NASDAQ Biotechnology Index rose about 3% in midday trading Friday to 3,636.45, the highest level since February. underperforming the overall NASDAQ Index in the past year, investors might be recognizing the hidden value of the firms' drug research and development, says Steve Chesney, an analyst for Atlantic Equities in London who covers large cap biotech firms worth more than $60 billion. Celgene, a biotechnology company which develops anti-inflammatory drugs for cancer and other diseases rose around 2% to $82.09 in early afternoon trading.

  • TheStreet.com13 days ago

    Amgen Is Ready to Breakout on the Upside

    In this daily bar chart of AMGN, below, we can see a number of bullish developments. The daily On-Balance-Volume (OBV) line shows an uptrend from November signaling more aggressive buying for months. In this weekly bar chart of AMGN, below, we can see an uptrend from late 2016.